01st week of 2019 patent applcation highlights part 8 |
Patent application number | Title | Published |
20190000706 | ROBOT MOUNTING ARRANGEMENT - A surgical robotic system comprising: a surgical robot arm ( | 2019-01-03 |
20190000707 | SURGICAL FRAME HAVING TRANSLATING LOWER BEAM AND METHOD FOR USE THEREOF - A surgical frame and method for use thereof is provided. The surgical frame is capable of reconfiguration before, during, or after surgery. The surgical includes a translating beam that is moveable between at least a first lateral position and a second lateral position. The translating beam is used to join a first support portion and a second support portion of the surgical frame to one another, and movement of the translating beam affords access to a patient receiving area. | 2019-01-03 |
20190000708 | FOOT FOR A ROBOTIC EXOSKELETON FOR ASSISTED WALKING OF PERSONS SUFFERING FROM LOCOMOTOR DISORDERS - The foot comprises three rigid foot segments, namely a middle foot segment arranged to be connected to a leg of the robotic exoskeleton, a front foot segment elastically connected to the front end of the middle foot segment by means of a first set of leaf springs, and a rear foot segment elastically connected to the rear end of the middle foot segment by means of a second set of leaf springs. The foot is preferably configured in such a manner that in the condition where the front foot segment and the rear foot segment are both in contact with the ground, and no load is applied onto the foot, the middle foot segment is not in contact with the ground, but is elastically suspended by means of the first and second sets of springs. | 2019-01-03 |
20190000709 | MASSAGE MACHINE - In the case of adopting a massage mechanism which is capable of mechanically treating a treatment region ranging from buttocks to thighs, it is ensured to prevent a user from feeling a discomfort feeling at a time of seating on a seat. A massage machine includes a seat massage mechanism which is provided inside a seat and performs a massage of a treatment region ranging from buttocks to thighs (treatment region including at least buttocks) of a user seating on the seat, and in this massage machine, a guide is arranged along a front and rear direction inside the seat allowing the seat massage mechanism to be movable in the front and rear direction. | 2019-01-03 |
20190000710 | Thoracic Spine Mobilization/ Manipulation Practitioner Support Tool - A thoracic manipulation tool for protecting the hands of a practitioner consists of a first distal phalanx-receiving slot, a second distal phalanx-receiving slot, and a third distal phalanx-receiving slot that are positioned along an inner surface of a gripping device. An elongated structural body of the gripping device ensures that an outer surface of the gripping device is pressed against the palm of the practitioner when the manipulation tool is in use. More specifically, when the distal phalanx of the middle finger, the ring finger, and the pinky finger are pressed against the inner surface, the outer surface is pressed against the palm of the user. The materialistic properties of the gripping device ensure that the practitioner can maintain a firm grip while executing the thoracic spine manipulation procedure. | 2019-01-03 |
20190000711 | APPARATUS FOR MASSAGING A BODY PART OF A USER - Disclosed is an apparatus for massaging a body part of a user comprising a housing formed from a flexible material, a interchangeable spherical resilient body received within the housing, the interchangeable spherical resilient body being made from soft material and at least one connecting material coupled to opposite ends of the housing, the at least one connecting material having a predetermined length. The flexible material may include a tube like fabric or mesh material. The interchangeable spherical resilient body may include at least different sizes, spherical or non-spherical shape, and different textures. | 2019-01-03 |
20190000712 | FIRE PREVENTION SYSTEM FOR A SAUNA - A method for fire prevention in a sauna includes the steps of monitoring a rise of heat radiation from a sauna heater, comparing the rise of the heat radiation to a normal set heat radiation rise curve, determining whether the rise of the heat radiation of the sauna heater deviates from a normal rise in heat radiation, and | 2019-01-03 |
20190000713 | CONTAINER SUCH AS A BLISTER PACK - A container including a panel which defines one or more pockets in the surface thereof, wherein the one or more pockets are for holding a product; a closure layer disposed on the panel for sealing the product in the pocket(s); and a peelable label disposed on the closure layer. The peelable label has a first portion and a second portion, wherein the first portion of the peelable label is permanently secured to the closure layer or the panel, and the second portion of the peelable label is releasably adhered to the closure layer. | 2019-01-03 |
20190000714 | PROPOFOL FORMULATIONS WITH NON-REACTIVE CONTAINER CLOSURES - A container storing a liquid anesthetic solution is disclosed. The container is sealed by a closure, and the liquid anesthetic solution includes an anesthetic being from 0.1% to 10% by weight of the liquid anesthetic solution, water, and a solvent. The container includes a material that is inert to the anesthetic, and the closure includes siliconized rubber, a fluoropolymer, or metal that is inert to the anesthetic. The concentration of the anesthetic in the liquid anesthetic solution stored in the container following a predetermined time period is at least 93% of a concentration of the anesthetic in the liquid anesthetic solution before the liquid anesthetic solution is stored in the container. | 2019-01-03 |
20190000715 | PERFORATING NEEDLE FOR FLASK WITH SEPTUM - A perforating needle intended to be inserted into a flask through a stopper or septum to inject and remove a fluid includes a pointed end for piercing the stopper and a cylindrical body. The central body includes a central channel through which the fluid may enter and leave the flask and a side wall having at least one lateral orifice. The orifice is in fluid communication with the central channel. A lower end of the orifice is, in use, essentially level with an inner face of the stopper. The orifice is extended toward the pointed end by at least one slot, a shape of which is essentially tangential to a flow of the fluid so as to channel the fluid along an axis of the needle. The side wall includes at least two diametrically opposite lateral orifices arranged on either side of a central island. | 2019-01-03 |
20190000716 | Needleless Syringe Connector Cap and Container - A needleless syringe connector cap to be provided to a container having an aperture at its top, said cap comprising an elastically deformable plastic valve body. Said valve body comprises a first and second passage, each passage extending through the valve body. Both passages comprise a cross-slit valve in the extreme lower end of said passage, embodied as an aeration valve. The first passage is adapted to receive a first tapered syringe tip and the second passage is adapted to receive a second tapered syringe tip, wherein when fluid is withdrawn from a container to which the cap is provided through the first (second) passage using a first (second) tapered syringe tip to which said first (second) passage is adapted, the second (first) cross-slit valve opens in response to an under pressure in said container resulting from said withdrawal, so as to aerate said container. | 2019-01-03 |
20190000717 | PRESSURE-REGULATING VIAL ADAPTORS - A vial adaptor can include a connector interface and/or a piercing member. The vial adaptor can include a regulator assembly. The regulator assembly can include a regulator base, a regulator nest coupled with the regulator base, and/or a storage chamber formed at least partially by one or both of the regulator base and regulator nest. The regulator assembly can include a cover connected to one or both of the regulator base and regulator nest and fitted around a radially outward portion of one or both of the regulator base and regulator nest. In some cases, the regular assembly includes a flexible enclosure connected to the regulator nest and configured to transition between a contracted configuration and an expanded configuration. In some cases, the flexible enclosure is inhibited from transitioning to the expanded configuration prior to removal or modification of the cover from the regulator assembly. | 2019-01-03 |
20190000718 | CONNECTOR SECTION - A locking element for a connector configured to connect two components of a fluid transfer system and a connector that comprises the locking element are described. The connector comprising the locking element is configured to provide continuous fluid channels between a first component and a second component of a fluid transfer system, the fluid is a hazardous drug and the connector is designated for safe and contamination-free transfer of said hazardous drug from first to second container while isolating the needle tips and causing no dangerous and harmful leaks. | 2019-01-03 |
20190000719 | PRE-FILLED DRINKING STRAW WITH A CROSS-SLIT VALVE CLOSURE ON BOTH ENDS - The invention is characterized in that the straw body ( | 2019-01-03 |
20190000720 | PATIENT ENTERAL HYDRATION - A device and method for enterally hydrating a patient with cooled fluids. The patient may be a paralyzed or limited upper body mobility patient with a functional gastrointestinal system who is nonetheless incapable or not fully capable of drinking unassisted. Here fluids are provided by a suspended container which also has a pouch to admit cooling material such as ice, but to keep the cooling material separate from the fluid. The container may also have optional graduation markings to allow for convenient estimation of fluid use, and an upper open and closeable cap to allow the container to be refilled. The container has a lower fluid conducting tube that terminates in a mouthpiece. The mouthpiece contains a fluid valve formed from at least one slit in an elastic material. Patient mouth force on the valve causes the slit to enlarge, thus enabling cooled fluid to flow into the patient. | 2019-01-03 |
20190000721 | TWO-COMPONENT SELF-ADHESIVE DENTAL COMPOSITION, STORAGE STABLE INITIATOR SYSTEM, AND USE THEREOF - The invention relates to a kit of parts comprising Part A and Part B, Part A comprising: component(s) comprising an ascorbic acid moiety, stabilizer(s) selected from sulphite(s), phosphite(s) or mixtures thereof, optionally polymerizable component(s) without acidic moieties, optionally polymerizable component(s) with acidic moieties, and optionally filler(s), Part B comprising polymerizable component(s) without acidic moieties, polymerizable component(s) with acidic moieties, transition metal component(s), organic peroxide(s), and optionally filler(s). The invention is also directed to an initiator system comprising component(s) comprising an ascorbic acid moiety, stabilizer(s) selected from sulphite(s), phosphite(s) or mixtures thereof transition metal component(s), organic peroxide(s). The kit of parts and redox initiator system are particularly useful in the dental and orthodontic field. | 2019-01-03 |
20190000722 | DENTAL ADHESIVE MATERIAL KIT - The present invention provides a dental adhesive material kit excellent in storage stability of the materials and exhibiting excellent bond durability to dentin by photopolymerization. The present invention is a dental adhesive material kit comprising a dental aqueous adhesive composition (A) and a dental curable composition (B), wherein: the dental aqueous adhesive composition (A) comprises a (meth)acrylic polymerizable monomer (a) containing an acid group, a vanadium compound (b), water (c), a (meth)acrylic polymerizable monomer (d) containing an amino group, and a polymerization inhibitor (i); the content of the polymerization inhibitor (i) is 25 to 1000 parts by weight per 100 parts by weight of the vanadium compound (b); and the dental curable composition (B) comprises a (meth)acrylic polymerizable monomer (e) containing no acid group, a hydroperoxide (f), a photopolymerization initiator (g), and a filler (h) and does not comprise a thiourea compound. | 2019-01-03 |
20190000723 | KIT OF PARTS FOR PRODUCING A GLASS IONOMER CEMENT, PROCESS OF PRODUCTION AND USE THEREOF - The invention relates to a kit of parts for preparing a glass ionomer composition for dental use, the kit of parts comprising a Powder Part P and a Liquid Part L, Powder Part P comprising: acid-reactive inorganic filler, Liquid Part L comprising: water, complexing agent, polyacid, either the Powder Part P or the Liquid Part L or the Powder Part P and the Liquid Part L comprising non-aggregated nano-sized particles based on silica or alumina, the composition obtained by combining the components of Powder Part P and Liquid Part L before hardening comprising the components in the following amounts: non-aggregated nano-sized particles: from 0.1 to 15 wt.-%, acid-reactive filler in an amount from 50 to 75 wt.-%, polyacid: 7 to 20 wt.-%, complexing agent: 0.5 to 3 wt.-%, water: 5 to 18 wt.-%, wt.-% with respect to the weight of the whole composition. | 2019-01-03 |
20190000724 | ARRAY OF ABSORBENT ARTICLES INCLUDING A FRAGRANCE ACCORD AND A LOTION COMPOSITION - An array of at least two commonly-branded absorbent articles, such as wipes products. The array includes a first wipes product and a second wipes product. Each wipes product may appeal to a different type of consumer, such as a light experience seeking consumer and a heavy experience seeking consumer. The first wipes product may include a first supply of wipes formed from a first substrate. The first supply of wipes is moistened with a first functional lotion composition including a first fragrance accord and a first lotion formula. The second wipes product may include a second supply of wipes formed from a second substrate. The second supply of wipes is moistened with a second functional lotion composition including a second fragrance accord and a second lotion formula. The second fragrance accord is different from the first fragrance accord, and the second lotion formula is different from the first lotion formula. | 2019-01-03 |
20190000725 | SOOTHING RASH WIPE SYSTEM - A soothing rash wipe system including a porous sheet. The porous sheet is impregnated with a diaper rash soothing composition. The diaper rash soothing composition is sodium bicarbonate based and provides soothing effects when applied to skin. The soothing rash wipe system provides a combination of a baby wipe with a baking soda solution to relieve and treat diaper rash, redness, and soreness. | 2019-01-03 |
20190000726 | TITANIUM DIOXIDE FINE PARTICLE-DISPERSED COMPOSITE PARTICLES AND COSMETIC - The titanium dioxide fine particle-dispersed composite particles ( | 2019-01-03 |
20190000727 | MAKEUP COSMETIC - The present invention provides a makeup cosmetic and method of manufacturing the same attained by a water-in-oil emulsion cosmetic supplemented with an oil-in-water emulsion as a water phase in which fine (nano-sized) oil droplets containing a solid oil and having a specified predetermined particle size are dispersed. Specifically, the present invention provides a makeup cosmetic comprising an oil-in-water-in-oil (O/W/O) composite emulsion in which an oil-in-water (O/W) emulsion is dispersed in an external oil phase, wherein the oil-in-water (O/W) emulsion comprises oil droplets having a number-average particle size of 200 nm or smaller and containing a solidified oil. | 2019-01-03 |
20190000728 | AQUEOUS COMPOSITION FOR CARING FOR AND/OR MAKING UP KERATIN MATERIALS COMPRISING MICROCAPSULES ENCAPSULATING AN OILY DISPERSION OF AT LEAST ONE REFLECTIVE AGENT - The present invention concerns a composition, in particular in the form of aqueous dispersion for caring for and/or making up keratin materials comprising, in a physiologically acceptable medium, a) one aqueous phase; and b) at least microcapsules comprising:—an inner core comprising at least a dispersion of at least one reflective agent, in particular bismuth oxychloride, in at least one oil, and—at least one outer shell formed of a wall-forming polymeric material surrounding the said core, the said outer shell comprising i) at least one wall-forming polymer, and ii) optionally at least one plasticizer and/or at least one opaque substance and/:or at least one fatty acid salt. The present invention concerns also a cosmetic process for caring for and/or making up keratinic materials, comprising application on said keratinic materials in particular on the skin of a composition as above defined. | 2019-01-03 |
20190000729 | ATOMIZED SPRAY FOR GRIP ENHANCEMENT - Provided by the invention are systems for applying antiperspirant grip enhancement compositions to a selected skin treatment area. Application of the antiperspirant grip enhancement composition is accomplished by forming the composition into a mist or spray using an atomizing spray dispenser. | 2019-01-03 |
20190000730 | DEODORANT COMPOSITIONS - This invention provides an effective, dermatologically safe composition based on partially carbonated magnesium hydroxide for use in cosmetic formulations. | 2019-01-03 |
20190000731 | Oral Care Product and Methods of Use and Manufacture Thereof - This invention relates to a dentifrice comprising (i) at least one source of ionic tin; and (ii) an antibacterial system comprising caprylyl glycol together with 3-phenyl-1-propanol, phenethyl salicylate, or both 3-phenyl-1-propanol and phenethyl salicylate, as well as to methods of using and of making these compositions. | 2019-01-03 |
20190000732 | TRANSPARENT HAIR LIGHTENING COMPOSITIONS, KITS, AND METHODS OF USE - The present disclosure relates to transparent ready-to-use hair bleaching compositions and compositions useful for preparing the transparent ready-to-use hair bleaching compositions. The transparent ready-to-use bleaching compositions typically include: (i) one or more oxidizing agents selected from the group consisting of persulfates, perborates, percarbonates, a salt thereof, and a mixture thereof; (ii) one or more non-acrylic thickening polymers; (iii) one or more acrylic polymers; (iv) hydrogen peroxide; (v) one or more polyurethane polyethers; and (vi) water. Kits and methods for bleaching hair also disclosed. | 2019-01-03 |
20190000733 | Oral Compositions For Anticavity And Desensitization Use - Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one E | 2019-01-03 |
20190000734 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS - A deodorant stick comprising at least 25% by weight liquid triglyceride; a primary antimicrobial having a water solubility of at most about 90 g/L at 25° C.; a fragrance composition comprising at least about 50% natural oils, essential oils, or a combination thereof; and a primary structurant with a melting point of at least 50° C.; said deodorant stick being free of an aluminum salt; and said deodorant stick having a hardness from about 70 mm*10 to about 140 mm*10, as measured by penetration with ASTM D-1321 needle. | 2019-01-03 |
20190000735 | HAIR CARE COMPOSITIONS COMPRISING A 2-PYRIDINOL-N-OXIDE MATERIAL AND AN IRON CHELATOR - The present invention is directed to a hair care composition having an effective amount of a 2-pyridinol-N-oxide material and an effective amount of an iron chelator; wherein the combination of the iron chelator and the 2-pyridinol-N-oxide material provides high anti-fungal efficacy. | 2019-01-03 |
20190000736 | DEODORANT AND ANTIPERSPIRANT COMPOSITIONS - A deodorant stick having a substituted or unsubstituted 2-pyridinol-N-oxide material and at least one material selected from the group consisting of hexamidine, magnesium carbonate, zinc carbonate, thymol, magnesium hydroxide, dead sea salt, calcium carbonate, polyvinyl formate, salycilic acid, niacinamide, and combinations thereof. | 2019-01-03 |
20190000737 | Personal Care Compositions Comprising a 2-Pyridinol N-Oxide Material and an Iron Chelator - A personal care composition having an effective amount of a 2-pyridinol-N-oxide material and an effective amount of an iron chelator; wherein the combination of the iron chelator and the 2-pyridinol-N-oxide material provides high antibacterial efficacy. | 2019-01-03 |
20190000738 | PHOTOPROTECTIVE COSMETIC COMPOSITION AND PROCESS FOR OBTAINING THE SAME - The invention relates to a composition, in particular a cosmetic composition, characterized in that it comprises:—at least one monoglyceride,—at least one tartaric ester of monoglycerides based on C12-C22,—at least one UV filter,—at least one HLB surfactant greater than 10, and—at least one hydrophilic gelling agent wherein the content of said one or more surfactant(s) having a HLB greater than 10 is comprised between 0.2% and 10% by weight, based on the total weight of the composition. | 2019-01-03 |
20190000739 | BLOCK POLYMER BEARING ALKOXYSILANE GROUPS AND COSMETIC USE THEREOF - The invention relates to a cosmetic process for caring for or making up keratin materials, comprising: either the topical application to the keratin materials of an anhydrous mixture of a cosmetic composition comprising a maleic anhydride block polymer and of an amino alkoxysilane compound; or the sequential application to the keratin materials of an anhydrous cosmetic composition comprising a maleic anhydride block polymer and of an anhydrous cosmetic composition containing an amino alkoxysilane, said block polymer comprising: a first block with a glass transition temperature (Tg) of greater than or equal to 40° C., obtained from a monomer CH | 2019-01-03 |
20190000740 | HYALURONIC ACID COMPOSITION - An injectable hyaluronic acid composition including a hyaluronic acid; a local anesthetic selected from the group consisting of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G′ of the composition caused by the local anesthetic upon sterilization by heat. Further, the medical and non-medical, such as cosmetic, use of such a composition, and to a method of manufacturing such a composition. | 2019-01-03 |
20190000741 | IOTA CARRAGEENAN-MULTI-VALENT CATION ALGINATE BINDER COMPOSITION - A toothpaste composition comprising a binder composition wherein said binder composition comprises (a) alginate comprising a polyvalent cation alginate and (b) carrageenan comprising iota carrageenan. Such binder composition provides desirable rheological properties coupled with unexpectedly enhanced processability and visual characteristics. | 2019-01-03 |
20190000742 | COSMETIC COMPOSITION FOR PEEL-OFF-TYPE PACKS, AND METHOD FOR PRODUCING SAME - A cosmetic composition for peel-off-type packs includes a thickener so that pearl or powder particles are stabilized in a formulation to thus impart a sophisticated and differentiated appearance. The content of an alcohol ingredient therein is controlled to accelerate drying, which maximizes a lifting effect. Silicone, imparting a feeling of conditioning, is introduced into polyvinyl alcohol and polyvinyl pyrrolidone, which are film formers, thus minimizing skin irritation upon peeling off. | 2019-01-03 |
20190000743 | A PROCESS FOR TREATING KERATIN SUBSTANCES USING A COMPOSITION COMPRISING A MODIFIED PHOTO-DIMERIZABLE POLYMER - The present invention relates to a general process for treating keratin substances, preferably keratin fibres, comprising the following steps: c) applying to the keratin substances a composition comprising at least one photo-crosslinkable polymer including at least one photo-dimerizable pendant group and at least one hydrophobic pendant group, and d) irradiating said composition on the keratin substances to crosslink the polymer. | 2019-01-03 |
20190000744 | PROCESS FOR TREATING KERATIN FIBRES WITH AN ETHYLENIC POLYMER BEARING A MALEIC ANHYDRIDE GROUP AND A POLYOL - Process for treating keratin fibres with an ethylenicpolymer bearing a maleic anhydride group and a polyol The invention relates to a cosmetic process for treating keratin fibres, comprising the application to the keratin fibres of a mixture of a maleic anhydride ethylenic polymer, a liposoluble polyol and an amine catalyst; said maleic anhydride ethylenic polymer being obtained by polymerization of: (a) 25% to 95% by weight, relative to the total weight of monomers, of an ethylenic monomer bearing an at least C8 linear or branched alkyl group; (b) 5% to 25% by weight of maleic anhydride; (c) 0% to 50% by weight of additional (meth)acrylate monomer; and a step of heating the keratin fibres to a temperature ranging from 90° C. to 250° C. The invention also relates to the crosslinked polymer obtained by reacting said ethylenic polymer with said liposoluble polyol. The treated keratin fibres have good water-resistant fixing properties. | 2019-01-03 |
20190000745 | POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF - Provided is a polymer-based antimicrobial composition that is non-toxic, water soluble, and that mitigates the transmission of infectious diseases from surfaces. The composition comprises a cationic polymer, at least one adhesion promoter, optionally organic and/or inorganic particles that are photocatalytically active in visible light, and a carrier, in which the components of the composition are not covalently bound to one another. Also provided is an antimicrobial composition that comprises at least (i) a polyethylenimine-based polymer and a carrier or (ii) an organic and/or inorganic particle that is photocatalytically active in visible light, an adhesion promoter, and a carrier. The antimicrobial compositions can be applied to disinfect a surface and to form residual self-sanitizing films on the surface that are removable. | 2019-01-03 |
20190000746 | HAIR-STYLING COMPOSITIONS COMPRISING A COMBINATION OF LATEX FILM-FORMING POLYMERS - The instant disclosure relates to hair styling compositions and products comprising the hair styling compositions. The hair styling compositions include: one or more soft latex film-forming polymers having a glass transition temperature (Tg) of less than 35° C. or less; one or more hard latex film-forming polymers having a glass transition temperature (Tg) of 35° C. or more; less than 15 wt. % of water; and at least 80 wt. % of one or more organic solvents, wherein the composition has a shear viscosity of up to about 70 cP at 23° C. The compositions may further comprise one or more propellants, and are useful in products such as aerosol hair sprays, pump hair sprays, hair mousses, hair foams, hair gels, etc. The disclosure further relates to methods for styling the hair using the compositions and products. | 2019-01-03 |
20190000747 | DEODORANT COMPOSITIONS - A deodorant stick comprising: at least about 25% of a liquid triglyceride; at least one antimicrobial; a primary structurant with a melting point of at least about 50° C.; and less than 8% of secondary structurants having a melting point of at least about 60° C.; said stick being free of an aluminum salt; and said stick having a hardness from about 80 mm*10 to about 140 mm*10, as measured by penetration with ASTM D-1321 needle. | 2019-01-03 |
20190000748 | PLANT LIPID COMPOSITION FOR PROMOTING HAIR GROWTH, METHOD FOR PROMOTING HAIR GROWTH AND USE OF SAID PLANT LIPIDS - The present invention is directed to cosmetic and/or pharmaceutical compositions comprising at least one plant lipid, preferably pataua ( | 2019-01-03 |
20190000749 | Polymer Implants for Treatment of Metabolic Disorders - Implantable devices including a biocompatible matrix configured for long term location in adipose tissue and a biologically active agent that can be carried by the matrix and delivered to the adipose tissue following implant therein. The biologically active agent can include a modulator or a precursor thereof that can directly or indirectly modify the gene expression of adipose cells, e.g., adipocytes, and thereby modify the presence or quantity of one or more expression products of the adipose tissue that may act locally on distant from the implant site in an endocrine fashion. Modulators can include small molecules (e.g., resveratrol), polynucleotides (e.g., RNAi), or polypeptides (e.g., antibodies or functional fragments thereof). | 2019-01-03 |
20190000750 | HYPOTONIC MICROBICIDAL FORMULATIONS AND METHODS OF USE - Hypotonic microbicidal compositions including an antimicrobial, such as an antiviral compound, and a pharmaceutically acceptable carrier in a solution formulation having hypotonic osmolarity have been developed for administration rectally to the gastrointestinal mucosa. In a preferred embodiment for use in preventing or decreasing HIV infection, the microbicidal is tenofovir, or a prodrug or derivative thereof. The formulations may include additional agents such as surfactants to enhance cleansing, buffers, or preservatives. Polymers may be included for osmolarity as well as comfort. | 2019-01-03 |
20190000751 | METHOD FOR MANUFACTURING A DRUG DELIVERY DEVICE AND A DRUG DELIVERY DEVICE MANUFACTURED ACCORDING TO THE METHOD - The invention relates to a method for producing a drug delivery device, which has a body comprising a siloxane-based elastomer and at least one active agent. The method comprises applying adhesive material, which comprises non-cured siloxane based elastomer, into a contact with the body and curing the said adhesive material by subjecting it to radiation energy from a laser source. The invention relates also to a drug delivery device manufactured according to the method. | 2019-01-03 |
20190000752 | ORGANIC NASAL TREATMENT SOLUTION - A nasal spray or therapy solution is provided having organic glycerin; an organic preservative system containing glycerin, | 2019-01-03 |
20190000753 | NASAL DOSAGE FORMS OF DIHYDROERGOTAMINE - The present application relates to a nasal dosage form of dihydroergotamine, wherein said dosage form requires less than about 15 minutes for administration and requires less than four sprays to administer effective dose of dihydroergotamine for treating migraine in human subjects. | 2019-01-03 |
20190000754 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE AND RELATED OCULAR SURFACE DISEASES - Compositions, kits, and methods for treating for treating dry eyes in mammal, particularly humans, are described. Such compositions include a pharmaceutically or veterinarily acceptable ocular carrier and a therapeutically effective amount of one or more immune regulatory agents, for example, stimulators and activators of regulatory B or T cells, type 2 immunity-associated immune cells, including group 2 innate lymphoid cells, type 2 CD4+ T helper cells, and alternative activation of macrophages (AAMacs, M2). | 2019-01-03 |
20190000755 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA - The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent. | 2019-01-03 |
20190000756 | ORAL PREPARATION AND PREPARATION METHOD THEREOF - An oral preparation for treating cell proliferation diseases. The oral preparation comprises hydroxylpropoxyl-β-cyclodextrin and an active component. The active component is KX2-361 or a medicinal salt thereof, and KX2-361 is represented by formula 1. By mixing hydroxylpropoxyl-ydcyclodextrin with KX2-361 or the medicinal salt thereof, an inclusion complex is formed, the solubility of the poorly-soluble drug KX2-361 is greatly improved, and accordingly the drug is prepared into an oral preparation. The oral preparation has good stability, high safety, good absorbability, high bioavailability and economical cost. | 2019-01-03 |
20190000757 | SELF-FILM-FORMING COMPOSITION FOR ORAL CARE - A self-film-forming composition in powder form, a reconstituted formula and a kit for oral use are provided, which allow an adequate colonization of the probiotic in the oral cavities together with a sufficient residence time to allow beneficial effects against the pathogens related with oral conditions. Thus, the items provided are useful for the prevention and/or treatment of a condition related to alterations of the oral microbiota, and specifically for peri-implantitis. The self-film-forming composition in powder form comprises at least a gelifier agent and/or at least a bioadhesive agent, and at least one lactic acid bacteria strain. | 2019-01-03 |
20190000758 | ANIMAL FEED BOLUS AND METHODS FOR MANUFACTURING THE SAME - The present invention relates to an animal feed bolus having two or more sections, wherein each section has a different composition. The different sections of the bolus are formulated to have different release times and/or to provide compositions with different nutritional purposes. Also described herein are methods for manufacturing such boluses, and methods for feeding an animal using such boluses. | 2019-01-03 |
20190000759 | ANTIMICROBIAL GEL CONTAINING SILVER NANOPARTICLES - A gel comprising nano-sized particles of metallic silver (Ag), a polymer comprising carboxylate groups, carboxylate molecules comprising at least one group capable of binding to Ag, and metal ions, where the gel is useful as a topically applied antimicrobial agent. | 2019-01-03 |
20190000760 | NANOPARTICLE-AQUEOUS DISPERSION LIQUID OF GLYCOSPHINGOLIPID - The purpose of the present invention is to provide a nanoparticle dispersion liquid of an α-galactosylceramide-related compound that can be administered in the form of a stable dispersion liquid using water as a solvent. According to the present invention, it is possible to obtain a nanoparticle dispersion liquid, which is not in the form of a liposome dispersion liquid obtained by using a phospholipid or the like, and also to control the size of nanoparticles. | 2019-01-03 |
20190000761 | METHODS OF TREATING ACNE USING NANOEMULSION COMPOSITIONS - The present invention relates to methods for treating and preventing acne or | 2019-01-03 |
20190000762 | EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST AND USES THEREOF - Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy. | 2019-01-03 |
20190000763 | PARTICULATE DELIVERY SYSTEMS - The present invention provides particulate delivery systems comprising plurality of particles comprising fenugreek gum and at least one pharmaceutically acceptable excipient. The particulate delivery systems of the present invention are used for the delivery of therapeutic, immunologic or diagnostic agents, and the like. | 2019-01-03 |
20190000764 | SINGLE-INJECTION METHODS AND FORMULATIONS TO INDUCE AND CONTROL MULTIPLE OVARIAN FOLLICLES IN BOVINE, CAPRINE, OVINE, CAMELID AND OTHER FEMALE ANIMALS - Methods and formulations for a simplified, single-injection method to induce and control the synchronous growth (superstimulation), and ovulation (superovulation) of multiple ovarian follicles in bovine, ovine, caprine, camelid and other female animals enabling the subsequent collection of (a) multiple oocytes when conducting in-vitro fertilization, or (b) multiple embryos when conducting multiple ovulation embryo transfer. | 2019-01-03 |
20190000765 | COMPRESSION-MOLDED PREPARATION - An object of the present invention is to provide a compression-molded preparation which has an excellent disintegration property and can be easily produced despite the use of granules coated with a polymer coating film having a function such as masking of an unpleasant taste. A compression-molded preparation achieving the above object is characterized by including granules obtained by coating a polymer-coated, granulated substance, in which a granulated substance containing a drug is coated with a polymer coating film, with one kind or two or more kinds of additives selected from the group consisting of a metal stearate, stearic acid, a sucrose fatty acid ester, talc, and silicic acid. | 2019-01-03 |
20190000768 | ENTERIC CAPSULE - There are manufactured an enteric capsule comprising: a seamless capsule consisting of a capsule fill and a shell layer; and an enteric coating layer on the shell layer, the enteric coating layer comprising one selected from a methacrylic acid-based polymer, polyvinyl acetate phthalate, organic acid ester of hydroxypropylmethylcellulose, carboxymethylethylcellulose, and cellulose acetate phthalate; and an enteric seamless capsule further comprising a subcoating layer between the shell layer of the seamless capsule and the enteric coating layer, the subcoating layer consisting of hydroxypropylcellulose and the like. The enteric seamless capsule has acid resistance and also enables controlled dissolution for each application site in the body. | 2019-01-03 |
20190000769 | Methods and Compositions Particularly for Treatment of Attention Deficit Disorder - There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described. | 2019-01-03 |
20190000770 | LOXAPINE FILM ORAL DOSAGE FORM - A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system. Advantageously, the film oral dosage form further includes a sweetener, a refreshing agent, an antioxidant, a pH stabilizer, a penetration enhancer, a mucoadhesive agent and a plasticizer. The loxapine film oral dosage form provides rapid onset of relief from acute agitation associated with schizophrenia or bipolar 1 disorder without presenting pulmonary health risks, thereby reducing risks to patients and others. | 2019-01-03 |
20190000771 | INTRASITE ADMINISTRATION AND DOSING METHODS AND PHARMACEUTICALS FOR USE THEREIN - A new method of targeted drug administration to wounds (surgical or traumatic), intrasite (IS), offers advantages in treatment efficacy and safety over traditional routes of administration. A novel method of dosing IS medications based on wound surface area provides the parameters for safe and effective dosing, a necessary advance for any FDA approval. Large IS doses increase risk of toxicity from impurities allowed in drugs given by other routes. Methods are presented for ultrapurification, particularly of endotoxins. Methods are presented for sterile delivery to the wound, to prevent aerosolization, and to homogenize application. Pharmacodynamic parameters make certain drugs advantageous as IS agents, including slow trans-wound surface diffusion, protein binding, and limited local tissue toxicity. Vancomycin is a prototypical drug with these features and is therefore very useful as an IS medication. Other drugs, including but not limited to rifaximin, possess similar pharmacodynamics and may be useful IS pharmaceuticals, delivered alone or in combination with other drugs, carriers, or materials. All of these attributes are advantages over traditional administration methods. | 2019-01-03 |
20190000772 | INTRASITE ADMINISTRATION AND DOSING METHODS AND PHARMACEUTICALS FOR USE THEREIN - A new method of targeted drug administration to wounds (surgical or traumatic), intrasite (IS), offers advantages in treatment efficacy and safety over traditional routes of administration. A novel method of dosing IS medications based on wound surface area provides the parameters for safe and effective dosing, a necessary advance for any FDA approval. Large IS doses increase risk of toxicity from impurities allowed in drugs given by other routes. Methods are presented for ultrapurification, particularly of endotoxins. Methods are presented for sterile delivery to the wound, to prevent aerosolization, and to homogenize application. Pharmacodynamic parameters make certain drugs advantageous as IS agents, including slow trans-wound surface diffusion, protein binding, and limited local tissue toxicity. Vancomycin is a prototypical drug with these features and is therefore very useful as an IS medication. Other drugs, including but not limited to rifaximin, possess similar pharmacodynamics and may be useful IS pharmaceuticals, delivered alone or in combination with other drugs, carriers, or materials. All of these attributes are advantages over traditional administration methods. | 2019-01-03 |
20190000773 | NON-INGESTIBLE TRANSDERMAL TAPE - A non-ingestible transdermal sports tape has an occlusive nonwoven pre-cut tape and night recovery therapy formulation, or a focus therapy formulation or a pre-workout therapy formulation. The occlusive nonwoven pre-cut tape includes a dosage amount pad positioned on one side of the occlusive nonwoven precut tape, an adhesive seal material disposed on a surface of the occlusive non-woven pre-cut tape, a liner material covering the dosage amount pad and the adhesive seal material. The adhesive seal material is configured to adhere to epidermis of an animal body preventing evaporation of water from epidermis while providing a removeable seal. Ingredients of the therapy formulations include non-fermented | 2019-01-03 |
20190000774 | TRANSDERMALLY ABSORBABLE PREPARATION - The present invention provides a transdermal absorption preparation in which a drug-containing adhesive layer is formed on a support, the aforementioned adhesive layer contains at least a thermoplastic elastomer and a higher fatty acid ester, and a content of a tackifier is not more than 10 wt %, which is superior in drug solubility and releasability, as well as adhesiveness to the skin and low irritation to the skin. | 2019-01-03 |
20190000775 | ASENAPINE-CONTAINING PATCH - The present invention provides a patch comprising a backing and an adhesive layer laminated on one side of the backing, wherein the adhesive layer comprises asenapine or a pharmaceutically acceptable salt thereof, an adhesive base and a low molecular weight amine. | 2019-01-03 |
20190000776 | METHOD FOR TREATING AN AUTOIMMUNE NEUROLOGICAL DISEASE AND/OR NEURODEGENERATIVE DISEASE AND PHARMACEUTICAL FORMULATIONS FOR A LIQUID DOSAGE FORM AND A CONTROLLED RELEASE DOSAGE FORM - A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: | 2019-01-03 |
20190000777 | USE OF DIHYDROXYACETONE IN PREPARATION OF ANTI-CANCER MEDICAMENTS - Provided is a use of dihydroxyacetone in the preparation of a medicament, the medicament being used for treating a cancer. | 2019-01-03 |
20190000778 | Dosage Forms and Related Therapies - This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role. | 2019-01-03 |
20190000779 | PHARMACEUTICAL FORMULATION - A method for the treatment of chronic pain and nutritional replacement is provided. In some implementations, the method consisting of parenteral administration to a patient of ketamine bolus in a dosage amount effective to treat pain followed by a parenteral administration to the patient of a composition comprising an effective amount ketamine, Vitamin C, Vitamin B6, and Vitamin D. | 2019-01-03 |
20190000780 | USE OF RASAGILINE FOR THE TREATMENT OF RESTLESS LEGS SYNDROME - Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof. | 2019-01-03 |
20190000781 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES - This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity. | 2019-01-03 |
20190000782 | COMBINATION MEDICATION FOR NEURO-DEGENERATIVE DISEASES AND SIDE-EFFECTS ASSOCIATED WITH COGNITION EFFECTING PHARMACEUTICALS - The disclosure generally relates to pharmaceutical compositions including a benzhydrylsulfinylacetamide antidepressant and an amount of sodium chloride effective to increase a mean arterial blood pressure of a subject and methods for ameliorating symptoms of dementia including forms of dementia diagnosed as Alzheimer's disease and side-effects associated with the administration of cognition effecting pharmaceuticals. | 2019-01-03 |
20190000783 | SKIN DISINFECTANT COMPOSITION - It is to provide a disinfectant liquid which enables easy identification of the application sites in preoperative skin disinfection and the like, where the liquid is obtained by coloring an aqueous solution of olanexidine gluconate which is a colorless and transparent liquid. A disinfectant liquid comprises olanexidine gluconate, a coloring agent such as Sunset Yellow FCF, an alkyl dimethylamine oxide such as lauryl dimethylamine oxide, and optionally one or more surfactants other than alkyl dimethylamine oxide such as polyoxyethylene alkyl ether including lauromacrogol and polyoxyethylene polyoxypropylene alkyl ether including polyoxyethylene(20) polyoxypropylene(4) cetyl ether. The disinfectant liquid enables easy identification of the application sites in preoperative skin disinfection and the like. | 2019-01-03 |
20190000784 | PULSATILE RELEASE PHARMACEUTICAL COMPOSITION COMPRISING NAFTAZONE OR ONE OF ITS SALTS - Disclosed is a pharmaceutical composition including naftazone or one of its pharmaceutically acceptable salts, for its use for the pulsatile release of naftazone or one of its pharmaceutically acceptable salts, wherein: a first pulse of naftazone or one of its pharmaceutically acceptable salts is released substantially immediately upon oral administration of the pharmaceutical composition; and at least one additional pulse of naftazone or one of its pharmaceutically acceptable salts is released at about 3 hours to about 8 hours following the oral administration. | 2019-01-03 |
20190000785 | Solid Solution Compositions and Use in Chronic Inflammation - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions. | 2019-01-03 |
20190000786 | METHODS OF DIAGNOSING AND TREATING INFECTED IMPLANTS - The present invention relates to methods for treating microbial infections on the surfaces of an implant or other surfaces near an implant in a patient. In particular, the methods are useful for treating biofilm infections. The methods include the use of minimally invasive techniques, including the use of ultra sound for facilitating the detection of biofilm infections on the implant or other surface of a patient and destroying the infection by administering an anthocyanin or an anthocyanidin or metabolite thereof. In particular, the administration of protocatechuic acid (PCA) or 2,4,6 trihydroxybenzaldehyde (2,4,6 THBA) for the treatment of an infected implant or other surface of a patient is described herein. | 2019-01-03 |
20190000787 | METHOD FOR PRODUCING EXTRACTS CONTAINING HYDROXYCINNAMIC COMPOUNDS FROM VEGETABLE WASTE PRODUCTS - The invention relates to a method for producing an extract containing hydroxycinnamic acids, characterised in that the method uses one or more vegetable waste products from the production of vegetable food products as a raw material, and comprising the following steps: a) selecting at least one waste product from at least one specific vegetable; b) extracting the hydroxycinnamic acids present in the waste product; c) separating the main liquid phase containing the extracted compounds from the solids; d) clarifying the liquid phase produced in step c); and e) concentrating the clarified liquid phase. The invention also relates to the extract produced via this production method, and the formulations containing this extract. | 2019-01-03 |
20190000788 | TREATMENT AND DIAGNOSIS OF COLON CANCER - The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods. | 2019-01-03 |
20190000789 | COMPOSITION AND METHOD FOR TREATING INFECTIONS CAUSED BY VANCOMYCIN-RESISTANT INFECTIOUS AGENTS IN A SUBJECT - The disclosure is related to vancomycin resistance and, in particular, to compositions comprising vancomycin for use in inhibiting growth of a vancomycin-resistant microorganism or for use in treating a subject infected with a vancomycin-resistant pathogen. In one aspect, the disclosure provides a composition comprising vancomycin and d-alanine. The disclosure also provides means and methods for treating a subject infected with a vancomycin-resistant microorganism. The disclosure further provides bacteria with a functionally deactivated gene in the vancomycin-resistance cluster. | 2019-01-03 |
20190000790 | PPAR-GAMMA ACTIVATORS AND THEIR THERAPEUTICAL USAGES - The invention relates to a composition for induction of activity of a nuclear receptor PPARy in a subject in need thereof, which comprises at least one of benzoate or a synergistic combination of benzoate and phenylacetate in association with a pharmaceutical carrier. | 2019-01-03 |
20190000791 | ISOTHIOCYANATOSTILBENES AS A NOVEL METHOD AND PRODUCT FOR TREATING CANCER - Products and methods for treating cancer in a human patient comprising administering to the patient therapeutically effective amount of a first pharmaceutically active agent, wherein the first pharmaceutically active agent is one of an isothiocyanatostilbene and a pharmacologically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, or a combination thereof. | 2019-01-03 |
20190000792 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING HIGH CONCENTRATION TAXANE - The present invention provides a pharmaceutical composition for oral administration, comprising (a) 4 to 40% by weight of a taxane, (b) 10 to 30% by weight of a medium chain triglyceride, (c) 30 to 70% by weight of monooleoyl glycerol, (d) 5 to 30% by weight of a surfactant, and (e) 10 to 30% by weight of polyoxyl glyceryl fatty acid ester and a process for preparing the same. | 2019-01-03 |
20190000793 | METHODS OF INDUCING ANESTHESIA - The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods. | 2019-01-03 |
20190000794 | TRANSMUCOSAL CANNABINOID FORMULATION INCLUDING A CHITOSAN EXCIPEINT - A cannabinoid formulation for transmucosal delivery includes a first excipient comprising shea butter containing at least 40% oleic acid, at least 20% steraic acid, at least 3% linoleic acid, and at least 2% palmitic acid, a second excipient comprising soy lecithin and a third excipient that is a glycolipid precursor. In one embodiment, the glycolipids precursor is a bioadhesive polysaccharide composed of randomly distributed β-(1→4)-linked D-glucosamine and N-acetyl-D-glucosamine to improve mucosal and cellular permeability. Preferably the polysaccharide is derived from naturally occurring chitosan. In one embodiment, the polysaccharide is naturally occurring chitosan having a concentration of between 1-20 mg/ml in the formulation. In an alternate embodiment, the polysaccharide is trimethylchitosan having a concentration of between 1-20 mg/ml in the formulation. | 2019-01-03 |
20190000795 | Methods of using cannabinoids and/or molecular similars for modulating, waking-up and/or disabling cellular functions involved in causing disease -- reinvigorating metabolism with anandamide, 2-arachidonoylglycerol and similarly acting compounds - Methods using cannabinoids and/or molecular similars for modulating, waking-up and/or disabling cellular functions involved in causing disease are provided for reinvigorating metabolism, including human metabolism. As humans age stresses they encounter cause their cells to respond opportunistically to counter each stress. Each of these responses involves at least minor shifts or compromises in metabolism. As these metabolic compromises multiply, metabolism continues to deviate from its optimum. Several lipophilic compounds are active in membranes of cells, including the plasma membrane, nuclear membrane, endoplasmic reticulum membrane and mitochondrial membrane. These lipophilic compounds, act with cannabinoid receptors to affect virtually all cell functions. By choosing specific endocannabinoids and/or analogues and targeting them at opportunistically deteriorated portions of metabolism through one of several specific endocannabinoid receptor proteins in a stepwise manner metabolism can be reinvigorated towards its optimal status. | 2019-01-03 |
20190000796 | ANTI-NOROVIRUS COMPOSITION AND UTILIZATION THEREOF - Provided are: a composition having an excellent anti-norovirus effect; use of a theaflavin compound for the preparation of the composition; and a method for preventing infection with a norovirus using a theaflavin compound. A theaflavin compound is used as an active ingredient for preventing infection with a norovirus. The theaflavin compound is preferably used together with an alcohol. The theaflavin compound is preferably one or more members selected from the group consisting of theaflavin, theaflavin-3-O-gallate, theaflavin-3′-O-gallate and theaflavin-3,3′-O-digallate that are derived from tea components. | 2019-01-03 |
20190000797 | TUMOR THERAPEUTIC AGENT - A novel tumor therapeutic agent for a combination therapy is disclosed. More specifically, a tumor therapeutic agent used for a combination therapy of lenvatinib, ifosfamide, and etoposide is disclosed. | 2019-01-03 |
20190000798 | APPLICATION OF DIMETHYLAMINO MICHELIOLIDE - The present invention provides an application of a dimethylamino micheliolide for preparing a pharmaceutical product for treating pulmonary fibrosis. | 2019-01-03 |
20190000799 | COMPOSITIONS AND METHODS FOR TREATING ALLERGIC INFLAMMATORY CONDITIONS - The invention provides methods of treating an allergic inflammatory condition characterized by inflammation of the squamous epithelium of a target tissue by reestablishing SPINK7 checkpoint control in the esophageal epithelium, and related compositions and methods. | 2019-01-03 |
20190000800 | COMPOSITION COMPRISING A DIINDOLYLMETHANE AND A RETINOID TO TREAT A SKIN CONDITION - Provided is a composition for use in treating a skin condition, the composition comprising:
| 2019-01-03 |
20190000801 | METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS - Methods are disclosed herein for administering a oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor for treating autoimmune and/or glomerulonephritis-associated diseases, and in particular, Systemic Lupus Erythematosus (SLE). | 2019-01-03 |
20190000802 | DRUG COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM - The invention provides preparations, formulations, kits and other products of manufacture (e.g., blister packs) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and methods of making and using them. The invention provides compositions and therapies comprising use of a beta adrenergic antagonist (also called “beta blockers”, e.g., propranolol) in combination with an anti-inflammatory agent, e.g., a nonsteroidal anti-inflammatory drug (NSAID), an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), an anabolic steroid, a natural oil or fatty acid or any combination thereof. | 2019-01-03 |
20190000803 | CHONDROITIN COMPLEXES FOR TRANSCUTANEOUS ABSORPTION - The present invention relates to the use of chondroitin as a transdermal carrier and slow-release system for active ingredients in pharmaceutical and cosmeceutical compositions. | 2019-01-03 |
20190000804 | METHODS OF USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOI- SOINDOLINE-1,3-DIONE - Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4. | 2019-01-03 |
20190000805 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions - Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein. | 2019-01-03 |
20190000806 | COMPOUNDS USEFUL AS KINASE INHIBITORS - This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases. | 2019-01-03 |
20190000807 | ORGANIC COMPOUNDS - The present invention relates to certain PDE2 inhibitory compounds, in free or salt form, pharmaceutical compositions containing such compounds and methods for the treatment of PDE2 mediated disorders. | 2019-01-03 |